A chronological record of peer-reviewed Semax research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Semaxworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Melanocortin & BDNF Signaling. Primary indications investigated: Cognitive enhancement, Neuroprotection, Stroke recovery, BDNF modulation.
Study in transgenic APP/PS1 Alzheimer disease model mice examining semax effects on cognitive function, beta-amyloid pathology, and tau.
Study examining semax effects on post-stroke neuroinflammation, microglial activation (Iba1+), and pro-inflammatory cytokine production.
Study measuring semax effects on neurotrophic factor expression (BDNF, NGF, GDNF mRNA) in injured and uninjured brain regions.
RCT of intranasal semax in patients with various optic neuropathies measuring visual acuity, visual field, and optic nerve imaging.
Study of semax effects on T-cell proliferation, immune cell subsets, and serum cytokine (IL-2, IL-6, TNF-alpha, IFN-gamma) levels.
Safety review synthesizing adverse event data from multiple semax clinical trials including stroke, cognitive enhancement, and optic neuropathy.
Mechanistic study in rats with transient middle cerebral artery occlusion examining semax effects on BDNF, TrkB activation, and synaptic plasticity.
Study in aged rats examining semax effects on hippocampal neurogenesis (BrdU+, doublecortin+), BDNF, and synaptic density.
RCT of semax as adjunct to standard antidepressant therapy in major depressive disorder measuring mood and cognitive symptoms.
Phase 2/3 RCT of semax (0.1% intranasal solution) versus placebo in acute ischemic stroke patients; measured NIHSS, mRS, and infarct volume.
Study documenting olfactory nerve fiber-mediated transport of intranasal semax directly to CNS, bypassing blood-brain barrier.
In-vitro neuroprotection study examining semax effects on glutamate-induced excitotoxicity, ROS production, and neuronal apoptosis.
Microdialysis study measuring semax effects on ventral tegmental area and nucleus accumbens dopamine, as well as prefrontal norepinephrine.
Study in rats with transient MCAO measuring semax effects on motor recovery, sensorimotor coordination, and functional outcome.
Study showing semax activates both dopaminergic and serotonergic systems, providing a mechanism for its cognitive effects.
Pharmacokinetic study of intranasal semax showing olfactory bulb-to-brain transit and regional accumulation in hippocampus and cortex.
RCT of intranasal semax (0.1%, 3 mcg) versus placebo in healthy volunteers measuring attention, memory, and processing speed.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Semax is L3 (Emerging Clinical Evidence): pilot human studies or limited clinical trials available. Treat each study as one data point, not a conclusion.
PeptideMark indexes 84 studies on Semax: 12 human studies, 45 animal studies, 18 in-vitro, and 9 reviews. The current evidence level is L3 — emerging clinical evidence.
The earliest indexed peer-reviewed study on Semax in the PeptideMark library was published in 2004 (Journal of Psychopharmacology). Research activity has continued through 2011.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on Semax has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.